Insight in the prediction of chemotherapy-induced nausea

James P. Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.
Supportive Care in Cancer (Impact Factor: 2.36). 08/2009; 18(7):869-76. DOI: 10.1007/s00520-009-0723-2
Source: PubMed


To identify risk factors for chemotherapy-related nausea.
We examined risk factors for nausea in 1,696 patients from three multicenter studies conducted from 1998 to 2004. All patients were beginning a chemotherapy regimen containing cisplatin, carboplatin, or doxorubicin. Nausea was assessed on a 1-7 scale four times a day for 4 days by diary.
First, average nausea for breast cancer patients receiving doxorubicin (mean = 2.31) was significantly greater than for other patients receiving doxorubicin (mean = 1.82), patients receiving cisplatin (mean = 1.88), and patients receiving carboplatin (mean = 1.45), Ps < 0.01. Second, mean nausea decreased steadily with age, P < 0.0001. Third, patients rating themselves more susceptible to nausea had significantly more nausea (adjusted mean = 2.51) than patients rating themselves less susceptible (adjusted mean = 1.92) and were 2.8 times more likely to experience severe nausea, Ps < 0.0001. Fourth, expected nausea was a significant predictor of average nausea, P = 0.034, but not severe nausea, P = 0.31. Last, no evidence that gender is a significant predictor of nausea in 299 patients with gender neutral cancers, P = 0.35.
Specific patient characteristics, especially younger age and perceived susceptibility to nausea, can help clinicians in the early identification of patients who are more susceptible to treatment-related nausea.

Download full-text


Available from: Ben Colagiuri, Sep 19, 2015
5 Reads
  • Source
    • "Colagiuri et al., 2012; Neukirch and Colagiuri, 2015), thereby raising questions about informed consent and the best way to frame side effect warnings (Colloca and Miller, 2011b; Colloca and Finniss, 2012). Furthermore, the clinical relevance of these nocebo-induced side effects is highlighted by the fact that expectancies often predict the severity of side effects, even for invasive treatments such as chemotherapy (Montgomery and Bovbjerg, 2000; Olver et al., 2005; Zachariae et al., 2007; Colagiuri et al., 2008; Colagiuri and Zachariae, 2010; Roscoe et al., 2010; Colagiuri et al., 2012). While the primary focus of the current review is on the placebo effect, the accumulating evidence for the nocebo effect highlights that it is not only important to understand how expectancies can enhance beneficial clinical outcomes, but also to understand how they can induce harm. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite its initial treatment as a nuisance variable, the placebo effect is now recognized as a powerful determinant of health across many different diseases and encounters. This is in light of some remarkable findings ranging from demonstrations that the placebo effect significantly modulates the response to active treatments in conditions such as pain, anxiety, Parkinson's disease, and some surgical procedures. Here, we review pioneering studies and recent advances in behavioral, neurobiological, and genetic influences on the placebo effect. Based on a previous developed conceptual framework, the placebo effect is presented as the product of a general expectancy learning mechanism in which verbal, conditioned and social cues are centrally integrated to change behaviors and outcomes. Examples of the integration of verbal and conditioned cues, such as instructed reversal of placebo effects are also incorporated into this model. We discuss neuroimaging studies that using well-established behavioral paradigms have identified key brain regions and modulatory mechanisms underlying placebo effects. Finally, we present a synthesis of recent genetics studies on the placebo effect, highlighting a promising link between genetic variants in the dopamine, opioid, serotonin, and endocannabinoid pathways and placebo responsiveness. Greater understanding of the behavioral, neurobiological, and genetic influences on the placebo effect is critical for evaluating medical interventions and may allow health professionals to tailor and personalize interventions in order to maximize treatment outcomes in clinical settings. Copyright © 2015. Published by Elsevier Ltd.
    Neuroscience 08/2015; 307. DOI:10.1016/j.neuroscience.2015.08.017 · 3.36 Impact Factor
  • Source
    • "Multiple factors are reported to influence the individual risk of a patient developing CINV [31]. These factors relate not only to the treatment protocol but also the patient’s lifestyle, mental state, and previous experience with nausea and vomiting in other settings [32-34]. Consequently, while the emetogenicity of the treatment protocol is the major determinant of CINV risk, a patient with multiple predisposing factors can experience significant levels of CINV despite being prescribed a low emetogenic chemotherapy regimen. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Preliminary research shows ginger may be an effective adjuvant treatment for chemotherapy-induced nausea and vomiting but significant limitations need to be addressed before recommendations for clinical practice can be made.Methods/design: In a double-blinded randomised-controlled trial, chemotherapy-naive patients will be randomly allocated to receive either 1.2 g of a standardised ginger extract or placebo per day. The study medication will be administrated as an adjuvant treatment to standard anti-emetic therapy and will be divided into four capsules per day, to be consumed approximately every 4 hours (300 mg per capsule administered q.i.d) for five days during the first three cycles of chemotherapy. Acute, delayed, and anticipatory symptoms of nausea and vomiting will be assessed over this time frame using a valid and reliable questionnaire, with nausea symptoms being the primary outcome. Quality of life, nutritional status, adverse effects, patient adherence, cancer-related fatigue, and CINV-specific prognostic factors will also be assessed. Previous trials in this area have noted limitations. These include the inconsistent use of standardized ginger formulations and valid questionnaires, lack of control for anticipatory nausea and prognostic factors that may influence individual CINV response, and the use of suboptimal dosing regimens. This trial is the first to address these issues by incorporating multiple unique additions to the study design including controlling for CINV-specific prognostic factors by recruiting only chemotherapy-naive patients, implementing a dosing schedule consistent with the pharmacokinetics of oral ginger supplements, and independently analysing ginger supplements before and after recruitment to ensure potency. Our trial will also be the first to assess the effect of ginger supplementation on cancer-related fatigue and nutritional status. Chemotherapy-induced nausea and vomiting are distressing symptoms experienced by oncology patients; this trial will address the significant limitations within the current literature and in doing so, will investigate the effect of ginger supplementation as an adjuvant treatment in modulating nausea and vomiting symptoms.Trial registration: Identifier: ACTRN12613000120774.
    BMC Complementary and Alternative Medicine 04/2014; 14(1):134. DOI:10.1186/1472-6882-14-134 · 2.02 Impact Factor
  • Source
    • "The main risk factor for the degree of CINV is the emetogenic potential of the chemotherapeutic agents (Jordan, Kasper, & Schmoll, 2005). However, several patient-related features have been identified, such as other medical disorders, depression , low alcohol intake, dysfunctional family relationships, young age, ethnicity, and genetic makeup (Bouganim et al., 2012; Bourdeanu et al., 2012; Molassiotis, Stamataki, & Kontopantelis, 2013; Roscoe et al., 2010; Shih, Wan, & Chan, 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The importance of nursing theory and models for the development of the nursing profession is becoming increasingly evident in literature. This article demonstrates the use of the Betty Neuman Systems Model (NSM) to assess, as well as determine the predictors of chemotherapy-induced nausea and vomiting (CINV) in patients diagnosed with breast cancer receiving doxorubicin-based chemotherapy. The selection of the model for practice reflects the congruency between the level of severity of CINV and the patient-related risk factors. In addition, the NSM was used to determine the appropriate nursing interventions necessary to strengthen the flexible lines of defense and the lines of resistance in addition to maintaining system stability.
    Research and theory for nursing practice 11/2013; 27(4):296-304. DOI:10.1891/1541-6577.27.4.296 · 0.36 Impact Factor
Show more